On April 6, the FDA approved a regimen of 500 mg/m2 of cetuximab (Erbitux, Lilly) every two weeks for K-Ras wild-type, EGFR-expressing metastatic colorectal cancer (mCRC). Data from a recent analysis confirmed the efficacy of this regimen in real-world patients with mCRC.
“Real-world data on cetuximab dosing practices and associated survival outcomes in patients with K-Ras wild-type metastatic colorectal cancer are limited,” said lead researcher Himani Aggarwal, MA, MPhil, PhD,